How proteomics reveals potential biomarkers in brain diseases

Expert Review of Proteomics

Volumn 2, Issue 6, 2005, Pages 901-913

  Schmidt, Oliver ^a   Schulenborg, Thomas ^a   Meyer, Helmut E ^a   Marcus, Katrin ^a   Hamacher, Michael ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

2D; Alzheimer; Biomarker; Brain; DIGE; HUPO; LC; Mass spectrometry; Parkinson; Proteomics; Schizophrenia

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; PARKIN; TAU PROTEIN; UBIQUITIN;

ALZHEIMER DISEASE; BIOINFORMATICS; BRAIN TISSUE; EVALUATION; FLUORESCENCE SPECTROSCOPY; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEOMICS; QUALITY CONTROL; REVIEW; SCHIZOPHRENIA; STANDARDIZATION;

ANIMALS; BIOLOGICAL MARKERS; BRAIN DISEASES; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 28544449259     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2.6.901     Document Type: Review

References (150)

1. Blennow K. CSF Biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn. 5, 661-672 (2005).
2. Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Ab42, Ab42/40 ratio and total tau. Neurobiol. Aging 25, 273-281 (2004).
3. Romeo MJ, Espina V, Lowenthal M et al. CSF protome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2, 57-70 (2005).
4. Marcus K, Schmidt O, Schaefer H et al. Proteomics - application to the brain. Int. Rev. Neurobiol. 61, 285-311 (2004).
5. Prince JT, Carlson MW, Wang R et al. The need for a public proteomics repository. Nature Biotechnol. 22, 471-472 (2004).
6. Terry DE, Umstot E, Desiderio DM. Optimized sample-processing time and peptide recovery for the mass spectrometric analysis of protein digests. J. Am. Soc. Mass Spectrom. 15, 784-794 (2004).
7. Bibl M, Esselmann H, Otto M et al. Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid β peptides. Electrophoresis 25, 2912-2918 (2004).
8. Terry DE, Desiderio DM. Between-gel reproducibility of the human cerebrospinal fluid proteome. Proteomics 3, 1962-1979 (2003).
9. Meyer HE, Klose J, Harnacher M. HBPP and the pursuit of standardisation. Lancet Neurol. 2, 657-658 (2003).
10. Harnacher M, Meyer HE. HUPO Brain Proteome Project: aims and needs in proteomics. Expert Rev. Proteomics 2, 1-3 (2005).
11. Snowdon DA. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139, 450-454 (2003).
12. Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study. J. Am. Geriatr. Soc. 44, 675-681 (1996).
13. Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA 277, 813-817 (1997).
14. Snowdon DA. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologie 37, 150-156 (1997).
15. Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 3, 345-354 (2004).
16. Pennington K, Cotter D, Dunn M. The role of proteomics in investigating psychiatric disorders. Br. J. Psychiatry 187, 4-6 (2005).
17. Fountoulakis M, Hardmeier R, Hoger H et al. Postmortem changes in the level of brain proteins. Exp. Neurol. 167, 86-94 (2001).
18. Li K, Hornshaw MP, van Minnen J, Smalla KH, Gundelfinger ED, Smit AB. Organelle proteomics of rat synaptic proteins: correlation-profiling by isotope-coded affinity tagging in conjunction with liquid chromatography-tandem mass spectrometry to reveal postsynaptic density specific proteins. J. Proteome Res. 4, 725-733 (2005).
19. Svensson M, Skold K, Svenningsson P, Andren PE. Peptidomics-based discovery of novel neuropeptides. J. Proteome Res. 2, 213-219 (2003).
20. Sitek B, Luttges J, Marcus K et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 5, 2665-2679 (2005).
21. Klose J. Large-gel 2D electrophoresis. Methods Mol. Biol. 112, 147-172 (1999).
22. Rabilloud T. Two dimensional gel electrophoresis in proteomics: old, old fashioned, but still climbs up the mountains. Proteomics 2, 3-10 (2002).
23. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutation in mammals. Humangenetik 26, 231-233 (1975).
24. Görg A, Postel W, Günther S, Weser J. Improved horizontal two-dimensional electrophoresis with hybrid isoelectric focusing in immobilized pH gradients in the first dimension and laying-on transfer to the second dimension. Electrophoresis 6, 599-604 (1985).
25. Dzandu JK, Johnson JF, Wise GE. Sodium dodecyl sulfate-gel electrophoresis: staining of polypeptides using heavy metal salts. Anal. Biochem. 174, 157-167 (1988).
26. Shaw J, Rowlinson R, Nickson J et al. Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Proteomics 3, 1181-1195 (2003).
27. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18, 2071-2077 (1997).
28. Wang H, Hanash S. Multi-dimensional liquid phase-based seperations in proteomics. J. Chromatogr. B 787, 11-18 (2003).
29. Link A. Multidimensional peptide separations in proteomics. Trends Biotechnol. 20, 8-13 (2002).
30. Wolters D, Washburn M, Yates JR III. An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 73, 5683-5690 (2001).
31. Guerrier L, Lomas L, Boschetti E. A simplified monobuffer multidimensional chromatography for high-throughput proteome fractionation. J. Chromatogr. A 1073, 25-33 (2005).
32. Misek D, Kuick R, Wang H et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 5, 3343-3352 (2005).
33. Fenn JB. Electrospray ionization for mass spectrometry of large biomolecules. Science 246, 64-71 (1989).
34. Karas M, Gluckmann M, Schafer J. Ionization in matrix-assisted laser desorption/ionization: singly charged molecular ions are the lucky survivors. J. Mass Spectrom. 35, 1-12 (2000).
35. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem. Rev. 101, 269-295 (2001).
36. Eng JK, McCormack AL, Yates JR III et al. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976-989 (1994).
37. Yates III JR, Eng JK, McCormack AL, Schieltz D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal. Chem. 67, 1426-1436 (1995).
38. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).
39. Zhang W, Chait BT. Propound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal. Chem. 72, 2482-2489 (2000).
40. Shevchenko A, Jensen ON, Podtelejnikov AV et al. Linking genome and proteome by mass spectrometry: largeHscale identification of yeast proteins from two dimensional gels. Proc. Natl Acad. Sci. USA 93, 14440-14445 (1996).
41. Spengler B, Kirsch D. Peptide sequencing by matrix assisted laser desorption mass spectrometry. Rapid Comm. Mass Spectrom. 6, 105-108 (1992).
42. Nagy Z. The last neural division: a unifying hypothesis for the pathogenisis of Alzheimer's Disease. J. Cell Mol. Med. 9, 531-541 (2005).
43. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Downs syndrome. Proc. Natl Acad. Sci. USA 82, 4245-4249 (1985).
44. Kang J, Lemaire HG, Unterbeck A et al. The precursors of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736 (1987).
45. Haas C, Selkoe DJ. Cellular processing of β-amyolid precursor protein and the genesis of amyloid β-peptide. Cell 75, 1039-1042 (1993).
46. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β-amyolid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697 (1993).
47. Gravina SA, Ho L, Eckman CB et al. Amyloid β-protein (A β) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A40 or Aβ42(43). J. Biol. Chem. 270, 7013-7016 (1995).
48. Fukumoto H, Asami-Odaka A, Suzuki N, Shimada H, Ihara Y, Iwatsubo T. Amyloid β protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of Aβ42(43) and association of Aβ40 with cored plaques. Am. J. Pathol. 148, 259-265 (1996).
49. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monodonals: evidence that an initially deposited species is Aβ42(43). Neuron 13,45-53 (1994).
50. Tamaoka A, Kondo T, Odaka A et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem. Biophys. Res. Commun. 205, 834-842 (1994).
51. Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643-648 (1995).
52. Vanderstichele H, Blennow K, D'Heuvaert N et al. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF. In: Progress in Alzheimer's and Parkinsons Disease. Fisher A, Hanin I, Yoshida M (Eds) 773-778, Plenum, NY, USA (1998).
53. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer's disease. Arch. Neurol. 57, 100-105 (2000).
54. Sunderland T, Linker G, Mirza N et al. Decreased β-amyloid 1-42 and increased tau level in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289, 2094-2103 (2003).
55. Ida N, Hartmann T, Pantel J et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22908-22914 (1996).
56. Schroder J, Pantel J, Ida N et al. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol. Psychiatry 2, 505-507 (1997).
57. Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481-496 (2002).
58. Lewczuk P, Esselmann H, Meyer M et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun. Mass Spectrom. 17, 1291-1296 (2003).
59. Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol Sci 44, 17-26 (1998).
60. Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau. Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease.J. Neurol. Sci. 158, 134-140 (1998).
61. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur. Neurol. 43, 155-160 (2000).
62. Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656 (2003).
63. Andreasen N, Vanmechelen E, Van de Voorde A et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J. Neurol. Neurosurg. Psychiatry 64, 298-305 (1998).
64. Itoh N, Arai H, Urakami K et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 50, 150-156 (2001).
65. Ishiguro K, Ohno H, Arai H et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci. Lett. 270, 91-94 (1999).
66. Kohnken R, Buerger K, Zinkowski R et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287, 187-190 (2000).
67. Hampel H, Buerger K, Kohnken R et al. Tracking Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 199-206 (2001).
68. Buerger K, Teipel SJ, Zinkowski R et al. Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threononine 231. Arch. Neurol. 59, 627-629 (2002).
69. Hu YY. Levels of nonphosphorylated and phosphorylted tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate- recyde enzyme-linked immunosorbent assay. Am. J. Pathol. 2, 1269-1278 (2002).
70. Buée L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev 33, 95-130 (2000).
71. Iqbal K, Alonso Adel C, El-Akkad E et al. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration. J. Neural Transm. Suppl. 62, 309-319 (2002).
72. Iqbal K, Alonso AD, Gondal JA et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J. Neural. Transm. Suppl. 59, 213-122 (2000).
73. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913-4917 (1986).
74. Lambert JC, Coyle N, Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. Med. Genet. 41, 104-112 (2004).
75. Ordovas JM. Apolipoprotein E isoform phenotyping methodology and population frequency with identicifation of ApoE1 and ApoE5 isoforms. J. Lipid Res. 28, 371-380 (1987).
76. Fukumoto H, Ingelsson M, Garevik N et al. ApoE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fuid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol. 183, 249-253 (2003).
77. Hesse C, Nilsson Cl, Blennow K et al. Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization- time of flight-mass spectrometry. Electrophoresis 22(9), 1834-1837 (2001).
78. Gomez-Isla T, West HL, Rebeck GW et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann. Neurol. 39, 62-70 (1996).
79. Mann DM, Iwatsubo T, Pickering-Brown SM, Owen F, Saido TC, Perry RH. Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 17, 81-84 (1997).
80. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. ApoE and Alzheimer's disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
81. Wang GP, Khatoon S, Iqbal K, Grundke-Iqbal I. Brain ubiquitin is markedly elevated in AD. Brain Res. 566, 146-151 (1991).
82. van Leeuwen FW, Kleijn DP, van den Hurk HH et al. Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279, 242-247 (1998).
83. Hope AD, de Silva R, Fischer DF, Hol EM, van Leeuwen FW, Lees AJ. Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. J. Neurochem. 86, 394-404 (2003).
84. Fischer DF, De Vos RA, Van Dijk R et al. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J. 17, 2014-2024 (2003).
85. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer's disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 639, 1-7 (1994).
86. Castgegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain: Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol Med. 33, 562-571 (2002).
87. Choi J, Levey AI, Weintraub ST et al. Oxidative modifications and downregulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinsons and Alzheimer's diseases. J. Biol. Chem. 279(13), 13256-13264 (2004).
88. Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids 25, 419-425 (2003).
89. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 1000, 1-7 (2004).
90. Choi J, Malakowsky CA, Talent JM et al. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293, 1566-1570 (2002).
91. Castegna A, Aksenov M, Thongboonkerd V et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain: Part II. Dihydropyrimidinase related protein II, α-enolase and heat shock cognate 71. J. Neurochem. 82, 1524-1532 (2002).
92. Liao L, Cheng D, Wang J et al. Proteomic amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061-37068 (2004).
93. Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer's patients. Neuroreport 13(5), 611-615 (2002).
94. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3(8), 1487-1494 (2003).
95. Puchades M, Hansson SF, Nilsson CL et al. Proteomic studies of potential cerebospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol Brain Res. 118(1-2), 140-146 (2003).
96. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer's disease. J. Alzheimer's Dis. 7, 125-133 (2005).
97. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4, 3943-3952 (2004).
98. Moore DJ, West AB, Dawson VL et al. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci. 28, 57-87 (2005).
99. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
100. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinsons disease. Nature Med. 10, 58-62 (2004).
101. Braak H, DelTridici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
102. Gotz ME, Gerstner A, Harth R et al. Altered redox state of platelet coenzyme Q1O in Parkinson's disease. J. Neural Transm. 107, 41-48 (2000).
103. Kikuchi A, Takeda A, Onodera H et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis, 9, 244-248 (2002).
104. Le WD, Rowe D, Jankovic J et al. Effects of cerebrospinal fluids from patients with Parkinson's disease on dopaminergic cells. Arch. Neurol. 56, 194-200 (1999).
105. Spillantini MG, Schmidt ML, Lee VM et al. α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
106. Gispert S, Del Turco D, Garrett L et al. Transgenic mice expressing mutant A53T human α-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24, 419-429 (2003).
107. Lo Bianco C, Ridet JL, Schneider BL et al. α-Synucleinopathy and selective doperminergic neurone loss. Proc. Natl. Acad. Sci. USA 99, 10813-10818 (2002).
108. Kirik D, Annett LE, Burger C et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein. Proc. Natl. Acad. Sci. USA 100, 2884-2889 (2003).
109. Outerio TF, Lindquist S. Yeast cells provide insight to α-synuclein biology and pathobiology. Science 302, 1772-1775 (2003).
110. Volles MJ, Lansbury PT, Rochet JC et al. Vesicle permeabilisation by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819 (2001).
111. Mezey E, Dehejia A, Harta G et al. α-synuclein in neurodegenerative disorders. Nature Med. 4, 755-757 (1998).
112. Wakabayashi K, Hayashi S, Kakita A et al. Accumulation of α-synuclein/NACP is a cytophatological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96, 445-452 (1998).
113. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392, 605-608 (1998).
114. Goldberg MS, Fleming SM, Palacino JJ et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of doperminergic neurons. J. Biol Chem. 278, 43628-43635 (2003).
115. Palacino JJ, Sagi D, Goldberg MS et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622 (2004).
116. Chung KK, Thomas B, Li X et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkins protective function. Science 304, 1328-1331 (2004).
117. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinsons disease. Nature 392, 451-452 (1998).
118. Maraganore DM, Lesnick TG, Elbaz A et al. UCH-L1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55, 512-521 (2004).
119. Saigoh K, Wang YL, Suh JG et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nature Genet. 23, 47-51 (1999).
120. Cookson MR. Pathways to Parkinsonism. Neuron 37, 7-10 (2003).
121. Niki T, Takahashi-Niki K, Taira T et al. DJBP: a novel DJ-1-binding protein. Mol. Cancer Res. 1, 247-261 (2003).
122. Taira T, Saito Y, Niki T et al. DJ-1 has a role in anti-oxidative stress to prevent cell death. EMBO Rep. 5, 213-218 (2004).
123. Moore DJ, Zhang L, Dawson TM et al. Amissense mutation (L166P) in DJ-1, linked to familial Parkinsons disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87, 1558-1567 (2003).
124. Valente EM, Bentivoglio AR, Dixon PH et al. Localisation of a novel locus for autosomal recessive early onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Geneti. 68, 895-900 (2001).
125. Nakajima A, Kataoka K, Hong M et al. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett. 201, 195-201 (2003).
126. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary early-onset parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
127. Vercauteren FG, Bergeron JJ, Vandesande F et al. Proteomic approaches in brain research and neuropharmacology. Eur. J. Pharmacol. 500, 385-398 (2004).
128. Kim SI, Voshol H, van OJ et al. Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem Res. 29, 1317-1331 (2004).
129. Edgar PF, Douglas JE, Cooper GJ et al. Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. Mol Psychiatry 5, 85-90 (2000).
130. Paulson L, Martin P, Persson A et al. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71, 526-533 (2003).
131. Paulson L, Martin P, Ljung E et al. Effects on rat thalamic proteome by acute subchronic MK-801-treatment. Eur. J. Pharmacol 505, 103-109 (2004).
132. Maurer I, Ziers S, Moller H et al. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 48, 125-136 (2001).
133. Wang Y, Xu R, Sasaoka T et al. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 20, 8305-8314 (2000).
134. Tallerico T, Novak G, Liu IS et al. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res. Mol Brain Res. 87, 160-165 (2001).
135. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Ann. Rev. Pharmacol. Toxicol. 42, 165-179 (2002).
136. Prabakaran S, Swatton JE, Ryan MM et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9, 684-697 (2004).
137. Pennigton K, Beasley CB, Dunn M et al. Proteome analysis of the anterior cingulate cortex in major psychiatric disorders. Biol. Psychiatry 55, 132-133 (2004).
138. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338, 506-511 (1998).
139. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry 71, 401-403 (2001).
140. Otto M, Wiltfang J, Cepek L et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeld-Jakob disease. Neurology 58, 192-197 (2002).
141. Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creuzfeld-Jakob disease from other dementias. Mol Psychiatry 8, 343-347 (2003).
142. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 74, 1210-1214 (2003).
143. Carr S, Aebersold R, Baldwin M et al. The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol Cell. Proteomics 3, 531-533 (2004).
144. Ball CA, Sherlock G, Parkinson H et al. Standards for microarray data. Science 298, 539 (2002).
145. Hanash S. HUPO initiatives relevant to clinical proteomics. Mol. Cell. Proteomics 3, 298-301 (2004).
146. Hanash S. Building a foundation for the human proteome: the role of the Human Proteome Organization. J. Proteome Res. 3, 197-199 (2004).
147. Hermjakob H, Montecchi-Palazzi L, Bader G et al. The HUPO PSI's molecular interaction format - a community standard for the representation of protein interaction data. Nature Biotechnol. 22, 177-183 (2004).
148. Hermjakob H, Montecchi-Palazzi L, Lewington C et al. IntAct: an open source molecular interaction database. Nucleic Acids Res. 32, 452-455 (2004).
149. Orchard S, Hermjakob H, Julian RK et al. Common interchange standards for proteomics data: public availability of tools and schema. Proteomics 4, 490-491 (2004).
150. Harnacher M, Klose J, Rossier J et al. 'Does understanding the brain need proteomics and does understanding proteomics need brains?' - Second HUPO HBPP Workshop hosted in Paris. Proteomics 4, 1932-1934 (2004).